FDA’s plan to ban hair relaxer chemical called too little, too late

In April, a dozen years after a federal agency classified formaldehyde a human carcinogen, the Food and Drug Administration is tentatively scheduled to unveil a proposal to consider banning the chemical in hair-straightening products.

AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of lung cancer, a

November 12, 2024

Cerebellar inhibitory interneurons essential for fear memory, study finds

An LSU Health New Orleans research study led by Siqiong June Liu, PhD, Professor of Cell Biology and Anatomy, has found that cerebellar inhibitory interneurons

September 13, 2023

AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast cancer study, potentially throwing a wrench into its ongoing

September 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.